Sujet(s)
Fièvre , Antiagrégants plaquettaires , Chlorhydrate de prasugrel , Humains , Chlorhydrate de prasugrel/effets indésirables , Chlorhydrate de prasugrel/usage thérapeutique , Antiagrégants plaquettaires/effets indésirables , Fièvre/induit chimiquement , Fièvre/traitement médicamenteux , Mâle , Adulte d'âge moyen , Fièvre médicamenteuseSujet(s)
Infarctus du myocarde , Chlorhydrate de prasugrel , Humains , Chlorhydrate de prasugrel/administration et posologie , Chlorhydrate de prasugrel/usage thérapeutique , Mâle , Infarctus du myocarde/traitement médicamenteux , Femelle , Adulte d'âge moyen , Sujet âgé , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/effets indésirables , Relation dose-effet des médicamentsRÉSUMÉ
For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most frequently implemented in ACS patients undergoing percutaneous coronary intervention (PCI) across the globe. Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, which, by design, studied DAPT versus no DAPT rather than the optimal DAPT duration. The average DAPT duration in this study was 9 months, not 12 months. Subsequent ACS studies, which were not designed to assess DAPT duration, rather its composition (aspirin with prasugrel or ticagrelor compared with clopidogrel) were further interpreted as supportive evidence for 12-month DAPT duration. In these studies, the median DAPT duration was 9 or 15 months for ticagrelor and prasugrel, respectively. Several subsequent studies questioned the 12-month regimen and suggested that DAPT duration should either be fewer than 12 months in patients at high bleeding risk or more than 12 months in patients at high ischemic risk who can safely tolerate the treatment. Bleeding, rather than ischemic risk assessment, has emerged as a treatment modifier for maximizing the net clinical benefit of DAPT, due to excessive bleeding and no clear benefit of prolonged treatment regimens in high bleeding risk patients. Multiple DAPT de-escalation treatment strategies, including switching from prasugrel or ticagrelor to clopidogrel, reducing the dose of prasugrel or ticagrelor, and shortening DAPT duration while maintaining monotherapy with ticagrelor, have been consistently shown to reduce bleeding without increasing fatal or nonfatal cardiovascular or cerebral ischemic risks compared with 12-month DAPT. However, 12-month DAPT remains the only class-I DAPT recommendation for patients with ACS despite the lack of prospectively established evidence, leading to unnecessary and potentially harmful overtreatment in many patients. It is time for clinical practice and guideline recommendations to be updated to reflect the totality of the evidence regarding the optimal DAPT duration in ACS.
Sujet(s)
Syndrome coronarien aigu , Bithérapie antiplaquettaire , Antiagrégants plaquettaires , Humains , Syndrome coronarien aigu/traitement médicamenteux , Syndrome coronarien aigu/thérapie , Antiagrégants plaquettaires/usage thérapeutique , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/effets indésirables , Hémorragie/induit chimiquement , Intervention coronarienne percutanée , Facteurs temps , Résultat thérapeutique , Chlorhydrate de prasugrel/usage thérapeutique , Chlorhydrate de prasugrel/administration et posologie , Chlorhydrate de prasugrel/effets indésirables , Calendrier d'administration des médicamentsRÉSUMÉ
BACKGROUND: The effects of aspirin-free strategy on bleeding and cardiovascular events in patients undergoing percutaneous coronary intervention with oral anticoagulation (OAC) have not been fully elucidated. METHODS AND RESULTS: We conducted the prespecified subgroup analysis based on the use of OAC, including vitamin K antagonist and direct oral anticoagulants, within 7 days before percutaneous coronary intervention in the STOPDAPT-3 (Short and Optimal Duration of Dual Antiplatelet Therapy-3) trial, which randomly compared prasugrel monotherapy (2984 patients) to dual antiplatelet therapy (DAPT) with prasugrel and aspirin (2982 patients) in patients with acute coronary syndrome or high bleeding risk. The coprimary end points were major bleeding events (Bleeding Academic Research Consortium types 3 or 5) and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke) at 1 month. Among 5966 study patients, there were 530 patients (8.9%) with OAC (no aspirin: N=248, and DAPT: N=282) and 5436 patients (91.1%) without OAC (no aspirin: N=2736, and DAPT: N=2700). Regardless of the use of OAC, the effects of no aspirin compared with DAPT were not significant for the bleeding end point (OAC: 4.45% and 4.27%, hazard ratio [HR], 1.04 [95% CI, 0.46-2.35]; no-OAC: 4.47% and 4.75%, HR, 0.94 [95% CI, 0.73-1.20]; P for interaction=0.82), and for the cardiovascular end point (OAC: 4.84% and 3.20%, HR, 1.53 [95% CI, 0.64-3.62]; no-OAC: 4.06% and 3.74%, HR, 1.09 [95% CI 0.83-1.42]; P for interaction =0.46). CONCLUSIONS: The no-aspirin strategy compared with the DAPT strategy failed to reduce major bleeding events irrespective of the use of OAC. There was a numerical excess risk of the no-aspirin strategy relative to the DAPT strategy for cardiovascular events in patients with OAC.
Sujet(s)
Syndrome coronarien aigu , Anticoagulants , Acide acétylsalicylique , Bithérapie antiplaquettaire , Hémorragie , Intervention coronarienne percutanée , Antiagrégants plaquettaires , Chlorhydrate de prasugrel , Humains , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/méthodes , Mâle , Acide acétylsalicylique/administration et posologie , Acide acétylsalicylique/effets indésirables , Acide acétylsalicylique/usage thérapeutique , Femelle , Sujet âgé , Hémorragie/induit chimiquement , Adulte d'âge moyen , Anticoagulants/administration et posologie , Anticoagulants/effets indésirables , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/effets indésirables , Administration par voie orale , Bithérapie antiplaquettaire/méthodes , Chlorhydrate de prasugrel/administration et posologie , Chlorhydrate de prasugrel/usage thérapeutique , Chlorhydrate de prasugrel/effets indésirables , Syndrome coronarien aigu/thérapie , Syndrome coronarien aigu/complications , Syndrome coronarien aigu/mortalité , Résultat thérapeutique , Facteurs de risque , Appréciation des risques , Facteurs tempsRÉSUMÉ
BACKGROUND: The comparative efficacy and safety of adjusted- and standard-dose prasugrel in East Asian patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) remain unclear. This study aimed to comparatively assess the ischaemic and bleeding outcomes of adjusted-dose (maintenance dose: 3.75 mg) and standard-dose (maintenance dose: 10 mg) prasugrel in East Asian patients with AMI undergoing PCI. METHODS: From a combined dataset sourced from nationwide AMI registries in Japan and South Korea (n = 17,118), patients treated with either adjusted- or standard-dose prasugrel were identified. Patients who did not undergo emergent PCI, those on oral anticoagulants, and those meeting the criteria of contraindication of prasugrel in South Korea (age ≥ 75 years, body weight < 60 kg, or history of stroke) were excluded. Major adverse cardiovascular events (MACE) and Thrombolysis in Myocardial Infarction (TIMI) major bleeding events were compared between the adjusted-dose (n = 1160) and standard-dose (n = 1086) prasugrel groups. RESULTS: Within the propensity-matched cohort (n = 702 in each group), no significant difference was observed in the in-hospital MACE between the adjusted- and standard-dose prasugrel groups (1.85% vs. 2.71%, odds ratio [OR] 0.68, 95% confidence interval [CI] 0.33-1.38, p = 0.286). However, the incidence of in-hospital major bleeding was significantly lower in the adjusted-dose prasugrel group than in the standard-dose group (0.43% vs. 1.71%, OR 0.25, 95% CI 0.07-0.88, p = 0.031). The cumulative 12-month incidence of MACE was equivalent in both groups (4.70% vs. 4.70%, OR 1.00, 95% CI 0.61-1.64, p = 1.000). CONCLUSIONS: Among East Asian patients with AMI undergoing PCI, those administered adjusted-dose prasugrel exhibited a lower risk of in-hospital bleeding events than those administered standard-dose prasugrel, while maintaining a comparable 1-year incidence of MACE.
Sujet(s)
Infarctus du myocarde , Intervention coronarienne percutanée , Chlorhydrate de prasugrel , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Études de cohortes , Relation dose-effet des médicaments , Peuples d'Asie de l'Est , Hémorragie/induit chimiquement , Hémorragie/épidémiologie , Japon/épidémiologie , Infarctus du myocarde/épidémiologie , Intervention coronarienne percutanée/méthodes , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/effets indésirables , Chlorhydrate de prasugrel/administration et posologie , Chlorhydrate de prasugrel/effets indésirables , Enregistrements , République de Corée/épidémiologie , Résultat thérapeutiqueRÉSUMÉ
There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are used to prevent ischemic outcomes in common diseases such as coronary and peripheral arterial disease and stroke. Clopidogrel, a prodrug, is the most used oral P2Y12 inhibitor and is activated primarily after being metabolized by a highly polymorphic hepatic cytochrome CYP2C219 enzyme. Loss-of-function genetic variants in CYP2C219 are common, can result in decreased active metabolite levels and increased on-treatment platelet aggregation, and are associated with increased ischemic events on clopidogrel therapy. Such patients can be identified by CYP2C19 genetic testing and can be treated with alternative therapy. Conversely, universal use of potent oral P2Y12 inhibitors such as ticagrelor or prasugrel, which are not dependent on CYP2C19 for activation, has been recommended but can result in increased bleeding. Recent clinical trials and meta-analyses have demonstrated that a precision medicine approach in which loss-of-function carriers are prescribed ticagrelor or prasugrel and noncarriers are prescribed clopidogrel results in reducing ischemic events without increasing bleeding risk. The evidence to date supports CYP2C19 genetic testing before oral P2Y12 inhibitors are prescribed in patients with acute coronary syndromes or percutaneous coronary intervention. Clinical implementation of such genetic testing will depend on among multiple factors: rapid availability of results or adoption of the concept of performing preemptive genetic testing, provision of easy-to-understand results with therapeutic recommendations, and seamless integration in the electronic health record.
Sujet(s)
Cytochrome P-450 CYP2C19 , Antagonistes des récepteurs purinergiques P2Y , Humains , Cytochrome P-450 CYP2C19/génétique , Cytochrome P-450 CYP2C19/métabolisme , Antagonistes des récepteurs purinergiques P2Y/usage thérapeutique , Administration par voie orale , Association américaine du coeur , États-Unis , Antiagrégants plaquettaires/usage thérapeutique , Clopidogrel/usage thérapeutique , Dépistage génétique/méthodes , Chlorhydrate de prasugrel/usage thérapeutique , Test pharmacogénomique , Ticagrélor/usage thérapeutiqueRÉSUMÉ
BACKGROUND: There was no study evaluating the effects of an aspirin-free strategy in patients undergoing complex percutaneous coronary intervention (PCI). OBJECTIVES: The authors aimed to evaluate the efficacy and safety of an aspirin-free strategy in patients undergoing complex PCI. METHODS: We conducted the prespecified subgroup analysis based on complex PCI in the STOPDAPT-3 (ShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-3), which randomly compared low-dose prasugrel (3.75 mg/d) monotherapy to dual antiplatelet therapy (DAPT) with low-dose prasugrel and aspirin in patients with acute coronary syndrome or high bleeding risk. Complex PCI was defined as any of the following 6 criteria: 3 vessels treated, ≥3 stents implanted, ≥3 lesions treated, bifurcation with 2 stents implanted, total stent length >60 mm, or a target of chronic total occlusion. The coprimary endpoints were major bleeding events (Bleeding Academic Research Consortium 3 or 5) and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke) at 1 month. RESULTS: Of the 5,966 study patients, there were 1,230 patients (20.6%) with complex PCI. Regardless of complex PCI, the effects of no aspirin relative to DAPT were not significant for the coprimary bleeding (complex PCI: 5.30% vs 3.70%; HR: 1.44; 95% CI: 0.84-2.47; P = 0.18 and noncomplex PCI: 4.26% vs 4.97%; HR: 0.85; 95% CI: 0.65-1.11; P = 0.24; P for interaction = 0.08) and cardiovascular (complex PCI: 5.78% vs 5.93%; HR: 0.98; 95% CI: 0.62-1.55; P = 0.92 and noncomplex PCI: 3.70% vs 3.10%; HR: 1.20; 95% CI: 0.88-1.63; P = 0.25; P for interaction = 0.48) endpoints without significant interactions. CONCLUSIONS: The effects of the aspirin-free strategy relative to standard DAPT for the cardiovascular and major bleeding events were not different regardless of complex PCI. (ShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-3 [STOPDAPT-3]; NCT04609111).
Sujet(s)
Acide acétylsalicylique , Maladie des artères coronaires , Calendrier d'administration des médicaments , Endoprothèses à élution de substances , Bithérapie antiplaquettaire , Évérolimus , Hémorragie , Intervention coronarienne percutanée , Antiagrégants plaquettaires , Chlorhydrate de prasugrel , Conception de prothèse , Humains , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/instrumentation , Intervention coronarienne percutanée/mortalité , Antiagrégants plaquettaires/effets indésirables , Antiagrégants plaquettaires/administration et posologie , Mâle , Facteurs temps , Femelle , Acide acétylsalicylique/administration et posologie , Acide acétylsalicylique/effets indésirables , Acide acétylsalicylique/usage thérapeutique , Sujet âgé , Adulte d'âge moyen , Résultat thérapeutique , Hémorragie/induit chimiquement , Hémorragie/prévention et contrôle , Facteurs de risque , Chlorhydrate de prasugrel/administration et posologie , Chlorhydrate de prasugrel/effets indésirables , Chlorhydrate de prasugrel/usage thérapeutique , Évérolimus/administration et posologie , Évérolimus/effets indésirables , Maladie des artères coronaires/thérapie , Maladie des artères coronaires/imagerie diagnostique , Maladie des artères coronaires/mortalité , Thrombose coronarienne/étiologie , Thrombose coronarienne/prévention et contrôle , Syndrome coronarien aigu/thérapie , Syndrome coronarien aigu/imagerie diagnostique , Alliages de chrome , Appréciation des risques , Association de médicamentsRÉSUMÉ
BACKGROUND: Over the past decade, major society guidelines have recommended the use of newer P2Y12 inhibitors over clopidogrel for those undergoing percutaneous coronary intervention for acute coronary syndrome. It is unclear what impact these recommendations had on clinical practice. METHODS AND RESULTS: All percutaneous coronary intervention procedures (n=534 210) for acute coronary syndrome in England and Wales (April 1, 2010, to March 31, 2022) were retrospectively analyzed, stratified by choice of preprocedural P2Y12 inhibitor (clopidogrel, ticagrelor, and prasugrel). Multivariable logistic regression models were used to examine odds ratios of receipt of ticagrelor and prasugrel (versus clopidogrel) over time, and predictors of their receipt. Overall, there was a significant increase in receipt of newer P2Y12 inhibitors from 2010 to 2020 (2022 versus 2010: ticagrelor odds ratio, 8.12 [95% CI, 7.67-8.60]; prasugrel odds ratio, 6.14 [95% CI, 5.53-6.81]), more so in ST-segment-elevation myocardial infarction than non-ST-segment-elevation acute coronary syndrome indication. The most significant increase in odds of receipt of prasugrel was observed between 2020 and 2022 (P<0.001), following a decline/plateau in its use in earlier years (2011-2019). In contrast, the odds of receipt of ticagrelor significantly increased in earlier years (2012-2017, Ptrend<0.001), after which the trend was stable (Ptrend=0.093). CONCLUSIONS: Over a 13-year-period, there has been a significant increase in use of newer P2Y12 inhibitors, although uptake of prasugrel use remained significantly lower than ticagrelor. Earlier society guidelines (pre-2017) were associated with the highest rates of ticagrelor use for non-ST-segment-elevation acute coronary syndrome and ST-segment-elevation myocardial infarction cases while the ISAR-REACT 5 (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome) trial and later society guidelines were associated with higher prasugrel use, mainly for ST-segment-elevation myocardial infarction indication.
Sujet(s)
Syndrome coronarien aigu , Clopidogrel , Intervention coronarienne percutanée , Guides de bonnes pratiques cliniques comme sujet , Chlorhydrate de prasugrel , Antagonistes des récepteurs purinergiques P2Y , Ticagrélor , Humains , Syndrome coronarien aigu/traitement médicamenteux , Syndrome coronarien aigu/chirurgie , Syndrome coronarien aigu/thérapie , Intervention coronarienne percutanée/tendances , Antagonistes des récepteurs purinergiques P2Y/usage thérapeutique , Mâle , Femelle , Ticagrélor/usage thérapeutique , Chlorhydrate de prasugrel/usage thérapeutique , Sujet âgé , Adulte d'âge moyen , Études rétrospectives , Pays de Galles , Clopidogrel/usage thérapeutique , Antiagrégants plaquettaires/usage thérapeutique , Types de pratiques des médecins/tendances , Angleterre , Adhésion aux directives/tendances , Infarctus du myocarde avec sus-décalage du segment ST/traitement médicamenteux , Infarctus du myocarde avec sus-décalage du segment ST/thérapie , Infarctus du myocarde avec sus-décalage du segment ST/chirurgie , Infarctus du myocarde sans sus-décalage du segment ST/traitement médicamenteux , Infarctus du myocarde sans sus-décalage du segment ST/chirurgie , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
The delicate balance between ischemic and bleeding risks is a critical factor in antiplatelet therapy administration. Clopidogrel and prasugrel, belonging to the thienopyridine class of antiplatelet drugs, are known for their variability in individual responsiveness and high incidence of bleeding events, respectively. The present study is centered on the development and assessment of a range of deuterated thienopyridine derivatives, leveraging insights from structure-pharmacokinetic relationships of clopidogrel and prasugrel. Our approaches were grounded in the molecular framework of clopidogrel and incorporated the C2-pharmacophore design from prasugrel. The selection of ester or carbamate substituents at the C2-position facilitated the generation of the 2-oxointermediate through hydrolysis, akin to prasugrel, thereby bypassing the issue of CYP2C19 dependency. The bulky C2-pharmacophore in our approach distinguishes itself from prasugrel's acetyloxy substituent by exhibiting a moderated hydrolysis rate, resulting in a more gradual formation of the active metabolite. Excessive and rapid release of the active metabolite, believed to be linked with an elevated risk of bleeding, is thus mitigated. Our proposed structural modification retains the hydrolysis-sensitive methyl ester of clopidogrel but substitutes it with a deuterated methyl group, shown to effectively reduce metabolic deactivation. Three promising compounds demonstrated a pharmacokinetic profile similar to that of clopidogrel at four times the dose, while also augmenting its antiplatelet activity. SIGNIFICANCE STATEMENT: Inspired by the structure-pharmacokinetic relationship of clopidogrel and prasugrel, a range of clopidogrel derivatives were designed, synthesized, and assessed. Among them, three promising compounds have been identified, striking a delicate balance between efficacy and safety for antiplatelet therapy. Additionally, the ozagrel prodrug conjugate was discovered to exert a synergistic therapeutic effect alongside clopidogrel.
Sujet(s)
Clopidogrel , Antiagrégants plaquettaires , Chlorhydrate de prasugrel , Clopidogrel/pharmacocinétique , Clopidogrel/pharmacologie , Antiagrégants plaquettaires/pharmacocinétique , Antiagrégants plaquettaires/pharmacologie , Antiagrégants plaquettaires/composition chimique , Humains , Chlorhydrate de prasugrel/pharmacocinétique , Chlorhydrate de prasugrel/pharmacologie , Cytochrome P-450 CYP2C19/métabolisme , Relation structure-activité , Activation métabolique , Mâle , Hydrolyse , Microsomes du foie/métabolisme , Microsomes du foie/effets des médicaments et des substances chimiquesRÉSUMÉ
BACKGROUND: The ISAR-REACT 5 trial compared the efficacy and safety of ticagrelor and prasugrel in patients with ACS managed invasively. The present study sought to investigate the impact of ticagrelor and prasugrel on the incidence and pattern of urgent revascularization in acute coronary syndromes (ACS) patients undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: This post-hoc analysis of the ISAR-REACT 5 trial included all ACS patients who underwent PCI. The primary endpoint for this analysis was the incidence of urgent revascularization at 12-month follow-up. Secondary outcome was the pattern of urgent revascularization procedures (namely, urgent target vessel/non-target vessel revascularization - TVR/NTVR). Among 3,377 ACS patients who underwent PCI, 1,676 were assigned to ticagrelor and 1,701 to prasugrel before PCI. After 12 months, the incidence of urgent revascularization was higher among patients assigned to ticagrelor as compared to prasugrel (6.8% vs. 5.2%; hazard ratio [HR] = 1.32, 95% confidence interval [CI] 1.00-1.75; p = 0.051), mostly attributable to significantly more urgent NTVR in the ticagrelor group (3.8% vs. 2.4%; HR = 1.62 [1.09-2.41]; p = 0.017). The risk of urgent TVR did not differ between treatment groups (3.3% vs. 3.0%; HR = 1.13 [0.77-1.65]; p = 0.546). CONCLUSIONS: In ACS patients treated with PCI, the cumulative rate of urgent revascularizations after 12 months is higher with ticagrelor compared to prasugrel, due to a significant increase in urgent revascularizations involving remote coronary vessels.
Sujet(s)
Syndrome coronarien aigu , Intervention coronarienne percutanée , Antiagrégants plaquettaires , Chlorhydrate de prasugrel , Ticagrélor , Humains , Ticagrélor/usage thérapeutique , Chlorhydrate de prasugrel/usage thérapeutique , Syndrome coronarien aigu/thérapie , Syndrome coronarien aigu/chirurgie , Mâle , Femelle , Intervention coronarienne percutanée/méthodes , Adulte d'âge moyen , Incidence , Antiagrégants plaquettaires/usage thérapeutique , Résultat thérapeutique , Sujet âgé , Études de suivi , Facteurs tempsRÉSUMÉ
BACKGROUND: The safety and feasibility of using 1-month dual antiplatelet therapy (DAPT) followed by P2Y12inhibitor monotherapy for patients after percutaneous coronary intervention (PCI) with thin-strut biodegradable polymer drug-eluting stents (BP-DES) in daily clinical practice remain uncertain. METHODSâANDâRESULTS: The REIWA region-wide registry is a prospective study conducted in 1 PCI center and 9 local hospitals in northern Japan. A total of 1,202 patients who successfully underwent final PCI using BP-DES (Synergy: n=400; Ultimaster: n=401; Orsiro: n=401), were enrolled in the registry, and received 1-month DAPT followed by P2Y12inhibitor (prasugrel 3.75 mg/day or clopidogrel 75 mg/day) monotherapy. The primary endpoint was a composite of cardiovascular and bleeding events at 12 months, including cardiovascular death, myocardial infarction (MI), definite stent thrombosis (ST), ischemic or hemorrhagic stroke, and Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding. Based on the results of a previous study, we set the performance goal at 5.0%. Over the 1-year follow-up, the primary endpoint occurred in 3.08% of patients, which was lower than the predefined performance goal (Pnon-inferiority<0.0001). Notably, definite ST occurred in only 1 patient (0.08%) within 1 year (at 258 days). No differences were observed in the primary endpoint between stent types. CONCLUSIONS: The REIWA region-wide registry suggests that 1-month DAPT followed by P2Y12inhibitor monotherapy is safe and feasible for Japanese patients with BP-DES.
Sujet(s)
Implant résorbable , Clopidogrel , Endoprothèses à élution de substances , Bithérapie antiplaquettaire , Intervention coronarienne percutanée , Antiagrégants plaquettaires , Antagonistes des récepteurs purinergiques P2Y , Enregistrements , Humains , Mâle , Sujet âgé , Femelle , Intervention coronarienne percutanée/effets indésirables , Adulte d'âge moyen , Antagonistes des récepteurs purinergiques P2Y/administration et posologie , Antagonistes des récepteurs purinergiques P2Y/effets indésirables , Antagonistes des récepteurs purinergiques P2Y/usage thérapeutique , Antiagrégants plaquettaires/usage thérapeutique , Antiagrégants plaquettaires/effets indésirables , Antiagrégants plaquettaires/administration et posologie , Clopidogrel/usage thérapeutique , Clopidogrel/effets indésirables , Clopidogrel/administration et posologie , Études prospectives , Japon , Bithérapie antiplaquettaire/méthodes , Hémorragie/induit chimiquement , Chlorhydrate de prasugrel/administration et posologie , Chlorhydrate de prasugrel/usage thérapeutique , Chlorhydrate de prasugrel/effets indésirables , Polymères , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: The effect of administering a crushed prasugrel loading dose is uncertain in patients presenting with a large myocardial infarction and ST-segment elevation myocardial infarction (STEMI). AIMS: The aim of this study was to investigate if patients with a large myocardial infarction may benefit from prehospital administration of a crushed prasugrel loading dose. METHODS: Patients from the CompareCrush trial with an available ambulance electrocardiography (ECG) were included in the study. An independent core laboratory confirmed a prehospital large myocardial area. We compared pre- and postprocedural angiographic markers, including Thrombolysis in Myocardial Infarction (TIMI) 3 flow in the infarct-related artery, high thrombus burden, and myocardial blush grade 3, in STEMI patients with and without a prehospital large myocardial area. RESULTS: Ambulance ECG was available for 532 patients, of whom 331 patients were identified with a prehospital large myocardial area at risk. Crushed prasugrel significantly improved postprocedural TIMI 3 flow rates in STEMI patients with a prehospital large myocardial area at risk (92% vs 79%, odds ratio [OR] 3.00, 95% confidence interval [CI]: 1.50-6.00) but not in STEMI patients without a prehospital large myocardial area at risk (91% vs 95%, OR 0.47, 95% CI: 0.14-1.57; pinteraction=0.009). CONCLUSIONS: Administration of crushed prasugrel may improve postprocedural TIMI 3 flow in STEMI patients with signs of a large myocardial area at risk on the ambulance ECG. The practice of crushing tablets of prasugrel loading dose might, therefore, represent a safe, fast and cost-effective strategy to improve myocardial reperfusion in this high-risk STEMI subgroup undergoing primary percutaneous coronary intervention.
Sujet(s)
Services des urgences médicales , Infarctus du myocarde , Intervention coronarienne percutanée , Infarctus du myocarde avec sus-décalage du segment ST , Humains , Infarctus du myocarde/traitement médicamenteux , Intervention coronarienne percutanée/effets indésirables , Antiagrégants plaquettaires/usage thérapeutique , Chlorhydrate de prasugrel/usage thérapeutique , Infarctus du myocarde avec sus-décalage du segment ST/traitement médicamenteux , Résultat thérapeutiqueRÉSUMÉ
Dual antiplatelet therapy (DAPT) is the cornerstone of maintenance medication following acute coronary syndromes (ST elevation myocardial infarction, non-ST elevation myocardial infarction, unstable angina). Over the last decade, P2Y12 inhibition in addition to low-dose acetylsalicylic acid has been intensively debated. In patients with acute coronary syndromes, balancing the reduction in cardiovascular events and increase in major bleeding during treatment with more potent P2Y12 inhibitors such as prasugrel and ticagrelor is still an issue. A special focus is on patients already treated with oral anticoagulants for stroke prevention in atrial fibrillation who require additional platelet inhibition following coronary stenting. This article summarizes the major recommendations given in the most recent Guideline for "Acute Coronary Syndromes" published by the European Society of Cardiology (ESC). The recommendations finally address strategies to reduce an increased bleeding risk based on clinical predictors.
Sujet(s)
Syndrome coronarien aigu , Infarctus du myocarde , Intervention coronarienne percutanée , Humains , Syndrome coronarien aigu/traitement médicamenteux , Antiagrégants plaquettaires/effets indésirables , Infarctus du myocarde/thérapie , Fibrinolytiques/effets indésirables , Acide acétylsalicylique/usage thérapeutique , Chlorhydrate de prasugrel/usage thérapeutique , Hémorragie/induit chimiquement , Hémorragie/traitement médicamenteux , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND AND PURPOSE: The optimal antiplatelet regimen after flow diverter treatment of cerebral aneurysms is still a matter of debate. A single antiplatelet therapy might be advantageous in determined clinical scenarios. This study evaluated the efficacy and safety of prasugrel single antiplatelet therapy versus aspirin and clopidogrel dual antiplatelet therapy. MATERIALS AND METHODS: We performed a post hoc analysis of 4 retrospective multicenter studies including ruptured and unruptured aneurysms treated with flow diversion using either prasugrel single antiplatelet therapy or dual antiplatelet therapy. Primary end points were the occurrence of any kind of procedure- or device-related thromboembolic complications and complete aneurysm occlusion at the latest radiologic follow-up (mean, 18 months). Dichotomized comparisons of outcomes were performed between single antiplatelet therapy and dual antiplatelet therapy. Additionally, the influence of various patient- and aneurysm-related variables on the occurrence of thromboembolic complications was investigated using multivariable backward logistic regression. RESULTS: A total of 222 patients with 251 aneurysms were included, 90 (40.5%) in the single antiplatelet therapy and 132 (59.5%) in the dual antiplatelet therapy group. The primary outcome-procedure- or device-related thromboembolic complications-occurred in 6 patients (6.6%) of the single antiplatelet therapy and in 12 patients (9.0%) of the dual antiplatelet therapy group (P = .62; OR, 0.712; 95% CI, 0.260-1.930). The primary treatment efficacy end point was reached in 82 patients (80.4%) of the single antiplatelet therapy and in 115 patients (78.2%) of the dual antiplatelet therapy group (P = .752; OR, 1.141; 95% CI, 0.599-2.101). Logistic regression showed that non-surface-modified flow diverters (P = .014) and fusiform aneurysm morphology (P = .004) significantly increased the probability of thromboembolic complications. CONCLUSIONS: Prasugrel single antiplatelet therapy after flow diverter treatment may be as safe and effective as dual antiplatelet therapy and could, therefore, be a valid alternative in selected patients. Further prospective comparative studies are required to validate our findings.
Sujet(s)
Acide acétylsalicylique , Clopidogrel , Anévrysme intracrânien , Antiagrégants plaquettaires , Chlorhydrate de prasugrel , Humains , Anévrysme intracrânien/imagerie diagnostique , Anévrysme intracrânien/thérapie , Chlorhydrate de prasugrel/usage thérapeutique , Chlorhydrate de prasugrel/administration et posologie , Femelle , Mâle , Antiagrégants plaquettaires/usage thérapeutique , Antiagrégants plaquettaires/administration et posologie , Études rétrospectives , Clopidogrel/usage thérapeutique , Clopidogrel/administration et posologie , Adulte d'âge moyen , Acide acétylsalicylique/usage thérapeutique , Acide acétylsalicylique/administration et posologie , Sujet âgé , Résultat thérapeutique , Bithérapie antiplaquettaire/méthodes , Thromboembolie/prévention et contrôle , Thromboembolie/étiologie , Adulte , EndoprothèsesRÉSUMÉ
Evidence on comparative effectiveness and safety of prasugrel and ticagrelor post-percutaneous transluminal coronary angioplasty is scarce in Indian population. In a 1:1 propensity score-matched cohort with 71 individuals in each group, the incidence of a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization was not significantly different in prasugrel and ticagrelor group (7.04% vs 9.86%; absolute difference, 2.8%; HR, 0.65; 95% CI, 0.21-2.1; p = 0.49). There was no significant difference in bleeding (5.63% vs 9.86%; absolute difference, -4.20%; 95% CI, -13.0%-4.5%) and dyspnea (7.04% vs 12.7%; absolute difference, -5.60%; 95% CI, -15.4%-4.1%).
Sujet(s)
Syndrome coronarien aigu , Chlorhydrate de prasugrel , Score de propension , Ticagrélor , Humains , Chlorhydrate de prasugrel/usage thérapeutique , Ticagrélor/usage thérapeutique , Syndrome coronarien aigu/thérapie , Mâle , Femelle , Adulte d'âge moyen , Résultat thérapeutique , Études rétrospectives , Antiagrégants plaquettaires/usage thérapeutique , Études de suivi , Intervention coronarienne percutanée/méthodes , Inde/épidémiologie , Antagonistes des récepteurs purinergiques P2Y/usage thérapeutique , Antagonistes des récepteurs purinergiques P2Y/effets indésirables , Antagonistes des récepteurs purinergiques P2Y/administration et posologie , Incidence , Angioplastie coronaire par ballonnet/méthodesRÉSUMÉ
Genotype based personalized antiplatelet therapy in the setting of percutaneous coronary intervention (PCI) has been studied in clinical trials. Despite the demonstrated risk associated with CYP2C19 loss-of-function (LoF) carriage in clopidogrel-treated PCI patients, real-world implementation of genotyping for PCI has been low. The goal of the current study was to provide CYP2C19 genotype information to the interventionalist prior to the completion of the catheterization to facilitate immediate personalized antiplatelet therapy. Routine personalization of P2Y12 inhibitor therapy for PCI in a community hospital cardiac catheterization laboratory by POC genotyping with the SpartanRx system was first offered in February 2017. A best practice advisory (BPA) based on the Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy was placed in the electronic health record prescription medication ordering system. By December 2019, 1,052 patients had CYP2C19 genotype testing, 429 patients underwent PCI with genotype guided antiplatelet therapy, and 250 patients underwent PCI without genotype testing and received antiplatelet therapy at the discretion of the treating physician. BPA compliance was 93. 87% of LoF allele carriers were prescribed ticagrelor or prasugrel whereas 96% of non-LoF allele carriers were prescribed clopidogrel. The genotyping results were available within 1 h and made immediately available for decision making by the interventional cardiologist. POC CYP2C19 genotyping is feasible in a community hospital catheterization laboratory and is associated with high rate of best practice compliance.Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03040622.
Sujet(s)
Cytochrome P-450 CYP2C19 , Intervention coronarienne percutanée , Humains , Clopidogrel/usage thérapeutique , Cytochrome P-450 CYP2C19/génétique , Génotype , Hôpitaux communautaires , Antiagrégants plaquettaires/usage thérapeutique , Chlorhydrate de prasugrel/usage thérapeutique , Résultat thérapeutique , Cathétérisme cardiaqueRÉSUMÉ
Low-dose prasugrel demonstrated a similar effectiveness profile to clopidogrel in East Asian ACS patients, but its comparison with another new-generation potent P2Y12 inhibitor, ticagrelor, remains unclear. To compare the effectiveness and safety of low-dose prasugrel against those of standard-dose ticagrelor in East Asian patients with ACS. This retrospective cohort study used Taiwan's National Health and Welfare Database. This study included ACS patients who underwent percutaneous coronary intervention and, at discharge between January 1, 2018 and December 31, 2020, were prescribed with low-dose prasugrel plus aspirin or standard-dose ticagrelor plus aspirin. Stabilized inverse probability of treatment weighting was used to balance the covariates across these two groups. The primary effectiveness outcome was a composite of acute myocardial infarction, ischemic stroke, and cardiovascular death; the secondary effectiveness outcome was each of the individual components of the primary outcome, transient ischemic attack, and repeat revascularization. The primary safety outcome was a composite of intracranial hemorrhage and gastrointestinal bleeding, and the two secondary safety outcomes were intracranial hemorrhage and gastrointestinal bleeding. A total of 24,807 patients were included in this study. Among them, 1,493 were low-dose prasugrel users and 23,314 were standard-dose ticagrelor users. No significant differences were found in primary effectiveness [HR: 0.97 (0.74-1.28)] or primary safety outcomes [HR: 1.22 (0.73-2.01)] between the two study groups. For East Asian patients with ACS, low-dose prasugrel provides comparable effectiveness without increasing bleeding risk compared to standard-dose ticagrelor. Low-dose prasugrel may be an appropriate alternative for East Asian populations.
Sujet(s)
Syndrome coronarien aigu , Chlorhydrate de prasugrel , Ticagrélor , Humains , Syndrome coronarien aigu/traitement médicamenteux , Acide acétylsalicylique/usage thérapeutique , Peuples d'Asie de l'Est , Hémorragie gastro-intestinale/étiologie , Hémorragies intracrâniennes/étiologie , Antiagrégants plaquettaires/usage thérapeutique , Chlorhydrate de prasugrel/usage thérapeutique , Antagonistes des récepteurs purinergiques P2Y/usage thérapeutique , Études rétrospectives , Ticagrélor/usage thérapeutique , Résultat thérapeutiqueSujet(s)
Syndrome coronarien aigu , Maladie coronarienne , Cardiopathies , Intervention coronarienne percutanée , Humains , Clopidogrel/usage thérapeutique , Ticagrélor/usage thérapeutique , Chlorhydrate de prasugrel/usage thérapeutique , Antiagrégants plaquettaires/usage thérapeutique , Antagonistes des récepteurs purinergiques P2Y/usage thérapeutique , Athérectomie , Résultat thérapeutiqueRÉSUMÉ
OBJECTIVE: This retrospective study aimed to investigate the potential impact of ticagrelor and clopidogrel treatment on cardiovascular outcomes in patients with anemia and acute coronary syndrome (ACS) and to provide insights into the optimal therapeutic approach for this vulnerable patient population. METHODS: A retrospective research design was employed, involving patients diagnosed with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) between 2014 and 2021. Inclusion criteria required a hemoglobin level below 12 mg/dL and a minimum 12-month P2Y12 inhibitor treatment. Comprehensive clinical, biochemical, and echocardiographic data were collected from the hospital's electronic repository. The primary efficacy endpoint was major adverse cardiovascular events (MACE), encompassing total mortality, cardiovascular mortality, reinfarction, ischemic stroke, and hemorrhagic stroke. Major hemorrhage was the primary safety endpoint. Secondary outcomes included total mortality, cardiovascular mortality, reinfarction, ischemic stroke, and hemorrhagic stroke, individually. RESULTS: Patients treated with ticagrelor (n = 118) and clopidogrel (n = 538) were compared. No significant difference was observed in major adverse cardiovascular events (MACE) and major bleeding between ticagrelor and clopidogrel treatment groups (MACE: clopidogrel 10.0% vs. ticagrelor 11.0%, p = 0.75; major bleeding: clopidogrel 2.8%, ticagrelor 2.5%, p = 0.88). Patients with hemoglobin levels ≤ 8 mg/dL demonstrated significantly higher MACE and major bleeding rates in the ticagrelor group (p = 0.008 and p = 0.002, respectively). Among patients aged ≥ 75 years, ticagrelor treatment was associated with a higher risk of major bleeding (p = 0.04). CONCLUSIONS: Ticagrelor and clopidogrel exhibited comparable efficacy and safety outcomes in anemic ACS patients over a one-year period. Although ticagrelor demonstrated superiority in reducing ischemic events, it is crucial to recognize the limitations of retrospective studies in informing clinical practice. This study offers valuable insights into tailoring antiplatelet therapy for anemic ACS patients and provides guidance for personalized treatment strategies, acknowledging the hypothesis-generating nature of retrospective analyses.
Sujet(s)
Syndrome coronarien aigu , Anémie , Accident vasculaire cérébral hémorragique , Accident vasculaire cérébral ischémique , Intervention coronarienne percutanée , Infarctus du myocarde avec sus-décalage du segment ST , Humains , Clopidogrel/effets indésirables , Ticagrélor/effets indésirables , Antiagrégants plaquettaires/effets indésirables , Études rétrospectives , Syndrome coronarien aigu/traitement médicamenteux , Accident vasculaire cérébral hémorragique/induit chimiquement , Accident vasculaire cérébral hémorragique/traitement médicamenteux , Intervention coronarienne percutanée/effets indésirables , Récidive tumorale locale/induit chimiquement , Récidive tumorale locale/traitement médicamenteux , Hémorragie/induit chimiquement , Anémie/étiologie , Accident vasculaire cérébral ischémique/traitement médicamenteux , Hémoglobines , Résultat thérapeutique , Chlorhydrate de prasugrel/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Data on P2Y12 inhibitors responsiveness from the middle east is scarce. We sought to investigate patient responsiveness to P2Y12 inhibitors within a cohort of major races that characterize the UAE population. The secondary objective was to assess risk factors for hyper and hypo-responsiveness in this population. METHODS: We conducted a cross-sectional study on adults who received either clopidogrel or ticagrelor treatments and had platelet responsiveness testing before undergoing neuro-endovascular interventions at our quaternary care hospital between March 2015 and April 2019. RESULTS: During the study period, 249 subjects met the inclusion criteria. Overall, 17.3 % were hyper-responsive and 25.7 % were hypo-responsive to P2Y12 inhibitors. When comparing between the P2Y12 inhibitors, rates of hyper-responsiveness were significantly higher to ticagrelor when compared to clopidogrel (11 versus 6 %, p = 0.02 respectively). Contrarily, hypo-responsiveness rates were significantly higher in clopidogrel treated patients compared to their ticagrelor treated counterparts (23 versus 2 %, p < .001 respectively). Patients of Middle-Eastern origin showed a significantly higher rate of hypo-responsiveness to both clopidogrel and ticagrelor when compared to other races (41.1 % and 26.7 %, P < 0.001 respectively). Asians showed the highest rates of hyper-responsiveness for both agents. Multivariate logistic regression analysis showed that proton pump inhibitors and statin combination, (OR: 6.39, 95 %CI [1.60, 25.392]), and Middle East vs. Indian subcontinent patients (OR: 4.67, 95 %CI [1.79-12.14]) were independent predictors of hypo-responsiveness to both P2Y12 inhibitors. CONCLUSION: This study demonstrated a high rate of hypo-responsiveness to P2Y12 inhibitors in a UAE cohort of patients undergoing neuro-endovascular procedures. In addition, therapeutic responsiveness to P2Y12 inhibitors varied markedly based on the racial background. Future larger studies are needed to evaluate genetic variations that may contribute to this rate of hypo-responsiveness in our population.